SEQUENT — Sequent Scientific Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapHigh Flyer

Annual income statement for Sequent Scientific, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2020 March 31st	2021 March 31st	R2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	Interim Report	ARS	PRESS
Standards:	IAS	IAS	—	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	11,792	13,616	14,128	14,209	13,697
Cost of Revenue
Gross Profit	5,281	6,099	6,198	5,148	6,100
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	10,541	12,048	13,550	15,022	13,794
Operating Profit	1,252	1,569	579	-813	-97
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	941	1,366	529	-1,377	-546
Provision for Income Taxes
Net Income After Taxes	820	1,045	448	-1,220	-296
Minority Interest
Net Income Before Extraordinary Items
Net Income	699	954	410	-1,212	-359
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	699	954	410	-1,212	-359
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	2.85	4.1	1.65	-3.2	-0.986
Dividends per Share